iCo Therapeutics Inc. is a Canada-based development stage pharmaceutical company. The Company is focused on the reprofiling and repositioning of drugs and drug candidates with a previous clinical history for new disease indications. iCo acquires candidates with identified targets and demonstrations of systemic safety, including reformulations of off‐patent drugs. The Company is developing iCo-007, a second generation antisense inhibitor targeting C-raf kinase messenger ribonucleic acid (mRNA), for the treatment of retinal neovascular diseases such as diabetic retinopathy (including diabetic macular edema). The iCo-008 (also known as Bertilimumab or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins that acts as messenger molecules between the cells of the immune system. The Company owns the exclusive rights to an oral Amphotericin B delivery system for life-threatening infections.